GMOs ban provides opportunity to cooperate, AND proves NATO says yes.
Giddings 22, L. Val Giddings is a senior fellow at the Information Technology and Innovation Foundation (ITIF). Giddings joined ITIF after nearly three decades of experience in science and regulatory policy relating to biotechnology innovations in agriculture and biomedicine. He works with ITIF to bring intellectual leadership to the examination of the constraints inhibiting innovations in these areas and devising remedies to those constraints., (Val, “Prospects for Transatlantic Cooperation in Biotech Policy—A US Perspective”, Information Technology and Innovation Forum, March 11, https://itif.org/publications/2022/03/11/prospects-transatlantic-cooperation-biotech-policy-us-perspective/) //CHC-DS
Many scientists in the EU (and around the world) knew from the beginning that this was the wrong approach, yet the EU pushed its model internationally, with aggressive diplomacy, leading to emulation by many countries in the developing world, with equally unhappy results to those seen in Europe.11 But a growing number of scientists, policymakers, and even “green” NGOs that had originally opposed GMOs, now recognize the counterproductive results of this approach and are working to avoid repeating the same mistakes with gene editing. This shines a spotlight on the most important and potentially fruitful opportunity for transatlantic cooperation in biotechnology: the revival of science-based regulatory regimes in which the degree of regulatory oversight is proportional to the hazards involved, and regulation that enables, rather than discourages the safe development of innovative products. A return to and reaffirmation of these first principles would provide fertile ground for cooperation and coordination globally. Regulatory reform (everywhere, not just in the EU and its emulators, though the need is greatest there) provides fertile ground for transatlantic cooperation and coordination. We have robust models of proven approaches.12 Without such cooperation, other progress in developing and deploying innovative solutions through biotechnology will be impeded or foregone.